Here s Why Raptor Pharmaceuticals Corp #marketing #pharmaceuticals

Posted On Sep 8 2017 by

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …


Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #astellas #pharma #inc

Posted On Aug 17 2017 by

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #pharmaceutical #industry #market #share

Posted On Aug 17 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Raptor Pharmaceutical Corp #diamond #pharma

Posted On Aug 9 2017 by

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …


Here s Why Raptor Pharmaceuticals Corp #pharma #iq

Posted On Aug 9 2017 by

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #verona #pharma

Posted On Aug 9 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Raptor Pharmaceutical Corp #generic #drug #company

Posted On Aug 2 2017 by

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #alliance #pharma

Posted On Aug 2 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …


Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #pharmaceutical #representative

Posted On Aug 2 2017 by

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …


Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #biggest #pharmaceutical #companies

Posted On Jul 25 2017 by

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …